NCT01029275 (SAPORO) is a NA clinical trial of Pre-treatment with octreotide in Acromegaly, sponsored by University Hospital, Rouen.

Who is sponsoring NCT01029275?

NCT01029275 is sponsored by University Hospital, Rouen.

What drugs are being tested in NCT01029275?

Interventions in NCT01029275: Pre-treatment with octreotide.

What condition does NCT01029275 study?

NCT01029275 studies Acromegaly.

Is NCT01029275 still recruiting?

NCT01029275 is currently completed. Last updated 30 July 2014.

Last reviewed 2014-07-30 · How we verify

NCT01029275: SAPORO

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Multicenter, Randomised Open Trial Comparing the Efficacy of a Medical Treatment With Sandostatin LP 30 mg Performed Before Surgery to a Prime Line transsphenoïdal Surgery in Previously Untreated Acromegalic Patients With Either a Micro or a Macro Pituitary Adenoma

Completed NA Last updated 30 July 2014

What this trial tests

NA trial testing Pre-treatment with octreotide in Acromegaly in 89 participants. Completed in 1 January 2012.

Timeline

1 January 2005

Primary endpoint
1 January 2012

1 January 2012

Quick facts

Lead sponsor	University Hospital, Rouen
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Enrollment	89
Start date	1 January 2005
Primary completion	1 January 2012
Estimated completion	1 January 2012
Sites	13 locations across France

Drugs / interventions tested

Pre-treatment with octreotide — full drug profile →

Conditions studied

Acromegaly — all drugs for Acromegaly →

Sponsor

University Hospital, Rouen

Who can join

Adults 18 to 80, any sex, with Acromegaly. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

IGF1 plasma levels
Time frame: 3 months and 12 months after transphenoidal surgery

Sponsor's own description

The aim of the study is to evaluate the interest of a six month pre-operative treatment with a long-acting somatostatin analog (Sandostatin LP) versus surgery alone in patients with a pituitary adenoma responsible for acromegaly.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Acromegaly

Currently open trials in the same condition.

NCT07037420 — ALXN2420 Versus Placebo in Combination With Somatostatin Analogs in Participants With Acromegaly · Phase 2 · recruiting
NCT05401084 — Diet in the Management of Acromegaly · NA · recruiting
NCT05131100 — Korean Regulatory Post Marketing Surveillance for Somavert · recruiting
NCT05964712 — Effects of Therapies in the Acromegaly Disease: Acral Morpho-functional Study · recruiting
NCT03158090 — The Longitudinal Approach to Acromegaly: A Pattern of Treatment and Comparative Effectiveness Research · recruiting

Other University Hospital, Rouen trials

Trials by the same sponsor.

NCT07441564 — Evaluation of the Efficacy of Ischemic Preconditioning to Protect Against Acute Kidney Injury After Open Surgery for Jux · NA · not yet recruiting
NCT07535944 — Prospective Exploration of Vascular Complications Associated With the Use of Immune Checkpoint Inhibitors · not yet recruiting
NCT07464184 — Evolution of Hypoxic Burden and Sympathetic/Parasympathetic Balance in Patients With Pulmonary Hypertension · NA · not yet recruiting
NCT07359885 — Prediction of Postoperative Pulmonary Complications in Thoracic Surgery · not yet recruiting
NCT07247500 — Impact of Reventilation After One-Lung Ventilation in Thoracic Surgery (OLVREEXP) · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01029275 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University Hospital, Rouen
Last refreshed: 30 July 2014

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01029275.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing